Listed by the USPTO as DABKOWSKI, ERINNE R
Tech Center 1600 • Art Units: 1654 1675 1683
This examiner grants 56% of resolved cases
DABKOWSKI, ERINNE R has resolved 721 cases, with an allowance rate of 55.8% and a median of 1061 days to allowance. The substantial record indicates an allowance outcome near the middle of the reported range, with a median timeline exceeding a short prosecution cycle.
The interview lift is 68.8%, making interviews a prominent consideration for prosecution strategy. The listed companies are The Regents of the University of Michigan, The Ohio State University, and The Chinese University of Hong Kong. The listed firms are Knobbe, Martens, Olson & Bear, LLP, Casimir Jones, S.C., and Clark+Elbing LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18313856 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | Final Rejection | The Regents of the University of Michigan |
| 18163773 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18294706 | COMPOSITIONS AND METHODS FOR TREATING MASTITIS | Non-Final OA | Zoetis Services LLC |
| 17782508 | VEGF MINI-TRAPS AND METHOD OF USE THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18428102 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Final Rejection | Ohio State Innovation Foundation |
| 18755185 | CELL-PENETRATING PEPTIDE SEQUENCES | Final Rejection | Ohio State Innovation Foundation |
| 16771641 | METHOD OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) WITH ROMIPLOSTIM | Non-Final OA | AMGEN INC. |
| 16954694 | COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17275764 | METHODS AND COMPOSITIONS FOR TREATING SKIN DISEASES | Final Rejection | VANDERBILT UNIVERSITY |
| 17925455 | Methods and Compositions for Treatment of Age-Related Dysfunction | Non-Final OA | The University of Tokyo |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17247153 | Methods for Inducing Intermittent Fasting and Modulating Autophagy | Final Rejection | The Chinese University of Hong Kong |
| 16427593 | Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities | Non-Final OA | The Chinese University of Hong Kong |
| 18007323 | NUTRITION FORMULATION | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 17634975 | PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER | Non-Final OA | Peptinovo Biopharma Inc. |
| 17283315 | Selective Binding and Aggregation of Human Keratin in the Skin Barrier Using Human Filaggrin Subdomains SD67 and SD150 | Final Rejection | YALE UNIVERSITY |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | Final Rejection | KYOWA HAKKO BIO CO., LTD. |
| 18674214 | Protective Agent Against Endothelial Dysfunction | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17672438 | COMPOSITIONS AND METHODS FOR INHIBITING BIOFILM DEPOSITION AND PRODUCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18030174 | GRIFFITHSIN FOR RHABDOVIRIDAE INFECTIONS | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 18697295 | LIPID MEDIATOR CHAPERONE AND USES THEREOF | Non-Final OA | The Children's Medical Center Corporation |
| 18685702 | GDF15 FUSION PROTEINS AND USES THEREOF | Non-Final OA | SUNSHINE LAKE PHARMA CO., LTD. |
| 18125007 | SECRETOGLOBIN FAMILY 1D MEMBER 2 (SCGB1D2) PROTEIN INHIBITS GROWTH OF BORRELIA BURGDORFERI AND AFFECTS SUSCEPTIBILITY TO LYME DISEASE | Non-Final OA | University of Helsinki |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.8% of resolved applications examined by Erinne R Dabkowski were allowed (721 resolved cases), compared with 48.2% across Art Unit 1654 over the last five years.
This examiner's interview lift is +68.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Erinne R Dabkowski took 1,061 days on average from filing to allowance.
Erinne R Dabkowski examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).